Protocol Ledger

NCT05660746 · Phase II/III · RECRUITING

Precise Infliximab Exposure and Pharmacodynamic Control

Interventional Phase II/III clinical trial protocol NCT05660746 sponsored by Children's Hospital Medical Center, Cincinnati in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-07-01 Enrollment: 180 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05660746
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)180 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05660746
Protocol FieldVerified Registry Value
NCT IdentifierNCT05660746
Consolidated Lead SponsorChildren's Hospital Medical Center, Cincinnati
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II/III
Overall Recruitment StatusRECRUITING
Registered Enrollment180 participants (ESTIMATED)
Registered Start Date2023-07-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Cincinnati Children's Hospital Medical Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI